Core Viewpoint - Changchun High-tech announced that its subsidiary, Jinsai Pharmaceutical, received approval for clinical trials of GenSci145 tablets, a novel selective PI3Kα inhibitor targeting PIK3CA mutation in advanced or metastatic solid tumors [1][2] Group 1: Product Development - GenSci145 is a first-class innovative chemical drug designed for treating locally advanced or metastatic solid tumors with PIK3CA mutations [1] - PIK3CA mutations are significant in breast cancer, accounting for 30%-40% of cases, and are crucial for tumor growth and resistance to treatments [1] Group 2: Clinical Need and Advantages - Existing PI3Kα inhibitors have poor targeting and can cause side effects like hyperglycemia, rash, and diarrhea, affecting long-term treatment adherence [2] - GenSci145 has shown selective inhibitory activity against various PIK3CA hotspot mutations and good blood-brain barrier penetration without traditional side effects, indicating its potential to meet clinical needs for patients with PIK3CA mutations and brain metastases [2] Group 3: Company Commitment - The company will actively advance the research and development of GenSci145 and comply with information disclosure obligations regarding project progress [2]

Core Viewpoint - Changchun Gaoxin (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received approval from the National Medical Products Administration for the clinical trial application of GenSci145 tablets, a novel selective PI3Kα inhibitor intended for the treatment of locally advanced or metastatic solid tumors with PIK3CA mutations [1] Group 1 - Jinsai Pharmaceutical's GenSci145 tablets are classified as a Class 1 innovative chemical drug [1] - The drug is specifically developed for patients carrying PIK3CA mutations [1] - The approval marks a significant milestone in the company's drug development pipeline [1]

Group 1 - The core announcement is that Changchun High-tech Industry (Group) Co., Ltd. has received approval from the National Medical Products Administration for the clinical trial application of GenSci145 tablets, a new selective PI3Kα inhibitor developed by its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. [2] - GenSci145 is aimed at treating locally advanced or metastatic solid tumors with PIK3CA mutations, which are prevalent in up to 40% of HR+/HER2- primary and metastatic breast cancers, indicating a significant market opportunity [2] - The current standard treatment for HR+/HER2- locally advanced or metastatic breast cancer involves endocrine therapy combined with CDK4/6 inhibitors, but there is a clinical need for targeted therapies like PI3K pathway inhibitors for patients with PIK3CA mutations who develop resistance [2] Group 2 - Early-stage PI3Kα inhibitors have shown significant improvements in progression-free survival (PFS) in clinical studies but have limitations due to toxicity issues, highlighting the need for new generation PI3Kα inhibitors [3] - GenSci145 has demonstrated strong selective inhibitory activity against various hotspot mutations in the PIK3CA gene in preclinical studies, showing clear efficacy and good safety profiles in animal models [3] - The successful progression of the clinical trial application for GenSci145 could enhance Changchun High-tech's business structure, optimize product offerings, and strengthen its competitive edge in strategic areas [3]

Core Viewpoint - The company, Changchun High-tech Industry (Group) Co., Ltd., announced that its subsidiary, GenSci Pharmaceutical Co., Ltd., has received acceptance for the clinical trial application of GenSci145 tablets from the National Medical Products Administration, which is aimed at treating locally advanced or metastatic solid tumors with PIK3CA mutations [1][2]. Group 1: Drug Information - Product Name: GenSci145 tablets [1] - Application: Clinical trial for domestic production [1] - Indication: Local advanced or metastatic solid tumors with PIK3CA mutations [1] - Acceptance Number: CXHL2501450, CXHL2501451, CXHL2501452 [1] Group 2: Clinical Context - PIK3CA mutations are found in up to 40% of HR+/HER2- primary and metastatic breast cancers, leading to significant risks of recurrence and mortality due to disease heterogeneity and resistance [2] - Current guidelines recommend endocrine therapy combined with CDK4/6 inhibitors as the first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer, but targeted therapies like PI3K pathway inhibitors are needed for patients with PIK3CA mutations who have developed resistance [2] Group 3: Development and Competitive Advantage - GenSci145 tablets are a new generation of mutation-selective PI3Kα inhibitors, showing strong selective inhibition of various hotspot mutations in preclinical studies, with clear efficacy and good safety profiles in animal models [2] - The drug has significant clinical development value and potential differentiation advantages, aiming to provide better treatment options for patients with PIK3CA mutations [2]

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received the acceptance notice from the National Medical Products Administration for the clinical trial application of GenSci145 tablets, a novel selective PI3Kα inhibitor developed by the company [1] Group 1 - GenSci145 tablets have demonstrated strong selective inhibitory activity against various hotspot mutations in the PIK3CA helix and kinase domains during preclinical studies [1] - The drug has shown clear efficacy and good safety characteristics in animal models, indicating its potential for clinical development [1] - GenSci145 tablets are expected to provide better treatment options for patients with locally advanced or metastatic solid tumors carrying PIK3CA mutations, highlighting its clinical development value and potential differentiation advantages [1]

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received the Acceptance Notice from the National Medical Products Administration for the clinical trial application of GenSci145 tablets, indicating a significant step in the drug's development process [1] Group 1: Product Development - GenSci145 is a novel selective PI3Kα inhibitor developed by Jinsai Pharmaceutical, demonstrating strong selective inhibitory activity against various hotspot mutations in the PIK3CA helix and kinase domains during preclinical studies [1] - The drug has shown clear efficacy and good safety characteristics in animal models, supporting its potential for clinical use [1] Group 2: Clinical Relevance - GenSci145 is expected to provide better clinical treatment options for patients with locally advanced or metastatic solid tumors carrying PIK3CA mutations, highlighting its clinical development value and potential differentiation advantages [1]

Core Viewpoint - Changchun High-tech announced that its subsidiary, Gensci Pharmaceutical, has received the Acceptance Notice from the National Medical Products Administration for the clinical trial application of GenSci145 tablets, a new selective PI3Kα inhibitor developed by Gensci [1] Group 1 - Gensci145 tablets have demonstrated strong selective inhibitory activity against various hotspot mutations in the PIK3CA helical and kinase domains during preclinical studies [1] - The drug has shown clear efficacy and good safety characteristics in animal models [1]

Core Viewpoint - Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. has officially applied for the new drug marketing authorization for its innovative drug PI3Kα inhibitor, Risoletin (development code: CYH33), to the Japanese Ministry of Health, Labour and Welfare (MHLW) [1] Group 1: Drug Development and Approval - The application is for the treatment of ovarian clear cell carcinoma (OCCC) with PIK3CA gene mutations in patients who have progressed or relapsed after chemotherapy [1] - Risoletin has previously received orphan drug designation from the MHLW [1] - The application is based on efficacy and safety data from the CYH33-G201 pivotal Phase II study, which is a multi-country, multi-center, open-label clinical trial [1] Group 2: Clinical Research and Efficacy - The global principal investigator for the study is Professor Wu Xiaohua from Fudan University Shanghai Cancer Center [1] - CYH33 is a novel, highly active selective inhibitor of phosphoinositide 3-kinase alpha (PI3Kα) with global intellectual property rights [1] - Preclinical studies indicate that CYH33 effectively and specifically inhibits PI3Kα kinase activity and demonstrates strong anti-tumor effects on tumor models with PIK3CA mutations [1] Group 3: Safety and Tolerability - Preliminary data from clinical trials suggest that CYH33 has good safety and tolerability, with controllable toxicity [2] - CYH33 is effective in treating various advanced solid tumors with PIK3CA mutations, including breast cancer, ovarian cancer, and endometrial cancer [2] - Ongoing clinical studies are evaluating CYH33 as a monotherapy or in combination with other anti-tumor drugs to assess its safety and efficacy in a broader range of advanced cancer patients [2]